Astrazeneca Ab

Eli Lilly and Company

Carey Horchler

Thomas Michael Bare

Shyamali Ghosh

Marc Chapdelaine

Daniel Sohn

John McCauley

Timothy Davenport

Edward Pierson

Markus Haeberlein

Rebecca Urbanek

Gary Steelman

Dean Brown

Megan Murphy

Wenhua Xiao

Edward Vacek

Christine Barlaam

Hui Xiong

Frances Marie McLaren

Vernon Alford

Giorgio Attardo

Shyamali (deceased) Ghosh

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Therapeutic heterocyclic compounds

Provided herein is a compound having the formula (I):Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTantagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Therapeutic chromone compounds

Compounds according to structural diagram (I) The following is an examiner's statement of reasons for allowance: In view of applicants' amendments to the claims which limit 'E' to phenyl or cycloalkyl groups the rejections of the previous action no longer pertain as they at best teach 'E' as alkyl.

1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain

A compound, 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, its (&#x2212;) enantiomer, its (+) enantiomer, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administering a pain-ameliorating effective amount of the (&#x2212;) enantiomer to an individual suffering from pain and pharmaceutical compositions containing the (&#x2212;) enantiomer are disclosed.

7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain

Compounds useful for the treatment of pain in accord with structural diagram (I), or tautomers or pharmaceutically-acceptable salts of such compounds, wherein R and A are as disclosed in the specification. Also disclosed are methods for the treatment of pain using compounds according to structural diagram (I) and pharmaceutical compositions comprising compounds according to structural diagram (I).

1, 2, 5, 10-tetrahydropyridazino&lsqb;4, 5-b&rsqb;quinoline-1,10-diones and their use for the treatment of pain

Growing community of inventors

Wilmington, DE, United States of America

Carey Horchler